Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. (25th April 2018) - Curto‐Barredo, L.; Spertino, J.; Figueras‐Nart, I.; Expósito‐Serrano, V.; Guilabert, A.; Melé‐Ninot, G.; Cubiró, X.; Bonfill‐Ortí, M.; Garcias‐Ladaria, J.; Villar, M.; García‐Navarro, X.; Bielsa‐Marsol, I.; et al.